Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a specialty pharmaceutical company focused on developing and commercializing innovative medicines for pain management. The company aims to provide effective pain relief while minimizing the potential for abuse. In the competitive pharmaceutical industry, Collegium faces competition from companies like Amphastar Pharmaceuticals, Syndax Pharmaceuticals, Enanta Pharmaceuticals, and Ironwood Pharmaceuticals.
Collegium's Return on Invested Capital (ROIC) is 9.78%, which is higher than its Weighted Average Cost of Capital (WACC) of 6.19%. This results in a ROIC to WACC ratio of 1.58, indicating that Collegium is generating returns that exceed its cost of capital. This suggests efficient use of capital, as the company is able to generate more value than the cost incurred to finance its operations.
In comparison, Amphastar Pharmaceuticals has a ROIC of 7.52% and a WACC of 6.01%, resulting in a ROIC to WACC ratio of 1.25. While Amphastar is also generating returns above its cost of capital, its efficiency is slightly lower than that of Collegium. This indicates that Collegium is more effective in utilizing its invested capital to generate returns.
Syndax Pharmaceuticals and Enanta Pharmaceuticals, on the other hand, show negative ROIC figures of -66.60% and -22.45%, respectively. Their ROIC to WACC ratios are -10.30 and -3.52, indicating that these companies are not generating sufficient returns to cover their cost of capital. This suggests inefficiencies in their capital utilization compared to Collegium.
Ironwood Pharmaceuticals stands out with a ROIC of 11.39% and a WACC of 4.02%, resulting in a ROIC to WACC ratio of 2.84. This makes Ironwood the most efficient among the peers analyzed, as it generates significantly higher returns relative to its cost of capital. While Collegium shows efficient capital use, Ironwood surpasses it in this comparison.
